Ardelyx Inc

ARDX

Company Profile

  • Business description

    Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

  • Contact

    400 Fifth Avenue
    Suite 210
    WalthamMA02451
    USA

    T: +1 510 745-1700

    E: [email protected]

    https://www.ardelyx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    395

Stocks News & Analysis

stocks

Undervalued ASX share with pathway to positive cash flow

Higher sales and a new loan facility increase our conviction.
stocks

Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand

We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks

Ahead of earnings, is Netflix a buy, a sell, or fairly valued?

Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,226.7045.900.50%
CAC 408,252.8760.25-0.72%
DAX 4025,286.0166.38-0.26%
Dow JONES (US)49,442.44292.810.60%
FTSE 10010,224.5214.42-0.14%
HKSE26,844.9678.66-0.29%
NASDAQ23,530.0258.270.25%
Nikkei 22553,936.17174.33-0.32%
NZX 50 Index13,718.1058.310.43%
S&P 5006,944.470.000.00%
S&P/ASX 2008,903.9048.100.54%
SSE Composite Index4,101.9110.69-0.26%

Market Movers